News & Events


Let's move, with Hymovis!

We are pleased to announce the release of our new website, designed with a user-friendly navigation, and updated with the latest information on the product. Our objective is to provide our international visitors with an easier way to learn about Hymovis and to browse information…

Global viscosupplementation market is anticipated to increase to over $2.64 billion by 2021

“Fidia Farmaceutici has invested in research and development of hyaluronic acid-based products for more than 70 years. Today, Fidia is growing its product portfolio with new, innovative solutions to meet challenges in the field of osteoarthritis using science, our legacy and our drive.”

PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronan (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA Inc., are projecting continued growth in 2017. The global viscosupplementation market is…

Management of sleep disorders may result in significant improvement of general health. The first step is talk to the primary care provider.

Social media use is rapidly increasing, as well as daytime and bedtime use of computers, including devices such as smartphones, tablets and laptops. Work, stress, menopause, advancing age or a variety of underlying medical conditions affecting the general population, may be responsible for those…

The Company is finalizing the acquisition of Italian Sooft/Oox Group

As announced at the end of 2016, Fidia has finalized the first step to the successful acquisition of the majority stake in the Sooft/Oox Group, through a legally binding agreement that will be executed over the next few weeks. Sooft/Oox is an Italian group active in the ophthalmic sector, with a…

An update from Fidia Farmaceutici

Further to previous communications, regarding the development of a hair loss remedy initiated a few months ago, we announce that the study is still in progress, thereby an accurate time frame in which such remedy would be available cannot be defined yet. Being a pharmaceutical manufacturing company…

HYMOVIS® offers a convenient two-dose regimen

Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common…

Designation by the US FDA for the treatment of advanced Dupuytren’s disease

Abano Terme, October 18, 2016 - Fidia Farmaceutici announced the obtainment of Orphan Drug Designation by the US Food and Drug Administration, for its Vibrio alginolyticus collagenase, produced and purified in the R&D Unit in Noto (Sicily), for the treatment of advanced Dupuytren’s disease…

A highly innovative and valuable contribution to healthcare professionals who work in contact with skin wounds

Fidia Farmaceutici SpA will take part in the 5th World Congress of the World Union of Wound Healing Societies "One Vision, One Mission”, in Florence, September 25-29 2016. WUWHS 2016 will offer an extensive scientific program including numerous symposia, training sessions, workshops and focus…

Born in Italy, globally successful

Fidia Farmaceutici celebrates its 70th Anniversary - the company was born in 1946, with great expectations and energy, as did Italy on the brink of a new era. It was 1946. We take pride in the things we do and are definitely proud of what we have achieved, along an 70-year incredible journey that…

For almost 20 years, Biofarmitalia has been designing, formulating and manufacturing its own products.

Founded in 1992 to develop new technologies for cosmetic and pharmaceutical applications, Biofarmitalia has gained expertise in doing research and manufacturing patches and dynamic devices designed for oral, dermal and transdermal controlled-release formulations of active ingredients. The…


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- ophthalmology
- wound care
- dermatology
- neurology
- dermo-aesthetics